<DOC>
	<DOCNO>NCT01161134</DOCNO>
	<brief_summary>The objective study determine relative bioavailability one 15 mg Meloxicam tablet ( Dr. Reddy . Laboratories Ltd. , Generics ) versus one 15 mg Mobic ( meloxicam ) Tablet ( Boehringer Ingelheim Pharmaceuticals Inc. , USA ) fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Meloxicam Tablets 15 mg Dr.Reddy 's Laboratories Limited Under Fasting Condition</brief_title>
	<detailed_description>Twenty eight ( twenty six study subject + two alternate subject ) healthy male and/or female subject participate open label , two-period , two-sequence , two- treatment , single dose , two-way crossover study least 14 day washout dos conduct fasting condition .</detailed_description>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>1 . The subject must healthy male female volunteer.If volunteer female . must demonstrate βCG level consistent nongravid state medical screen visit checkin Period 1 agree remain abstinent use doublebarrier contraception ( partner use condom female volunteer use diaphragm , contraceptive sponge , spermicide , IUD ) . If female postmenopausal surgically sterile , exempt requirement . ( Postmenopausal define menses previous 1 year . If cessation menses within 18 month , FSH and/or LH must document prestudy elevate postmenopausal range. ) . 2 . The subject must age 18 55 year old ( inclusive ) . 3 . The Subject 's body mass index ( BMI ) must within 19.0 30.0 ( Kg/m2 ) . 4 . The subject must nonsmoker use nicotine product . 5 . The subject must sign write consent form ( Research Subject Information Consent Form ) prior study entry . 6 . The subject must clinically acceptable result screen procedure include blood pressure , heart rate , ECG , physical exam , medical history , hematology , biochemistry , urinalysis . infection screen ( Hepatitis B Antigen , Hepatitis C Antibody , HIV ) 1 . Subjects history clinically significant gastrointestinal , dermatological , cardiovascular , renal , hematological , neurological , hepatic , pulmonary , endocrine disease last 12 month . 2 . Subjects determine Investigator medical condition may affect absorption , distribution , metabolism excretion investigational product , could jeopardize health prejudice result ( e.g . history surgery gastrointestinal tract , except appendectomy ) . 3 . Subjects know allergy meloxicam ( Mobic ) nonsteroidal antiinflammatory drug ( NSAIDS ) [ e.g . Motrin® ( ibuprofen ) , Celebrex® ( celecoxib ) . Vioxx® ( rofecoxib ) . Naprelan® Anaprox® , ( naproxen sodium ) , Lodine® ( etodolac ) , Cataflam® ( diclofenac potassium ) . Voltaren® Arthrotec® ( diclofenac sodium ) , etc. ] . 4 . Females pregnant , breastfeeding , likely become pregnant . 5 . Subjects clinically significant illness within four week prior Period 1 dosing . 6 . Subjects positive saliva alcohol test checkin period . 7 . Subjects history alcohol , drug substance abuse past 12 month . 8 . Subjects use prescription medication within 14 day Period 1 dose overthecounter medication within 14 day Period 1 dosing . 9 . Subjects deem uncooperative noncompliant . 10 . Subjects consume alcohol within 48 hour prior Period 1 Period 2 dosing . 11 . Subjects consume xanthinecontaining product ( include caffeine , theobromines , etc . ) within 48 hour prior Period 1 dosing . 12 . Subjects consume food beverage contain grapefruit ( e.g . fresh , Canned , frozen ) within 14 day prior administration study medication . 13 . Subjects abnormal diet within 30 day prior Period 1 dosing . 14 . Subjects participate investigational drug study donate 100 mL blood within 30 day prior Period 1 dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2004</verification_date>
</DOC>